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ARTICLE
Selective small molecule PARG inhibitor causes
replication fork stalling and cancer cell death
Jerry H. Houl1, Zu Ye1,9, Chris A. Brosey 1,9, Lakshitha P.F. Balapiti-Modarage2,3, Sarita Namjoshi1,
Albino Bacolla 1, Daniel Laverty4, Brian L. Walker2,3, Yasin Pourfarjam5, Leslie S. Warden1,
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Zachary D. Nagel 4, Tom Ellenberger7, In-Kwon Kim 5,7*, Darin E. Jones 2,3, Zamal Ahmed1* &
John A. Tainer 1*
Poly(ADP-ribose)ylation (PARylation) by PAR polymerase 1 (PARP1) and PARylation removal
by poly(ADP-ribose) glycohydrolase (PARG) critically regulate DNA damage responses; yet,
conﬂicting reports obscure PARG biology and its impact on cancer cell resistance to PARP1
inhibitors. Here, we found that PARG expression is upregulated in many cancers. We
employed chemical library screening to identify and optimize methylxanthine derivatives as
selective bioavailable PARG inhibitors. Multiple crystal structures reveal how substituent
positions on the methylxanthine core dictate binding modes and inducible-complementarity
with a PARG-speciﬁc tyrosine clasp and arginine switch, supporting inhibitor speciﬁcity and a
competitive inhibition mechanism. Cell-based assays show selective PARG inhibition and
PARP1 hyperPARylation. Moreover, our PARG inhibitor sensitizes cells to radiation-induced
DNA damage, suppresses replication fork progression and impedes cancer cell survival. In
PARP inhibitor-resistant A172 glioblastoma cells, our PARG inhibitor shows comparable
killing to Nedaplatin, providing further proof-of-concept that selectively inhibiting PARG can
impair cancer cell survival.
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Poly(ADP-ribose)ylation (PARylation) by PAR polymerase 1(PARP1) and its reversal by PAR glycohydrolase (PARG)dictate multiple DNA damage responses1–3. PAR home-
ostasis regulates DNA damage responses by rapid and dynamic
modulation of protein–protein and protein–DNA interactions
essential for genomic integrity and cell survival2. Consequently,
blocking PAR synthesis by PARP inhibitors (PARPi) impairs
signaling and the repair of damaged DNA4 and causes centro-
some ampliﬁcation5. Accordingly, PARP1-null mice are more
susceptible to carcinogenesis induced by DNA alkylating
agents6,7. In contrast, PARP1 hyperactivation causes excessive
PAR accumulation that is cytotoxic and triggers the release of
apoptosis-inducing factor (AIF) from mitochondria, leading to
cell death8,9. Similarly, mice lacking PARG show excessive PAR
accumulation, resulting in early embryonic lethality and cell
death10; whereas, PARG-deﬁcient cells exhibit delayed repair of
DNA single- and double-strand breaks (DSBs)11,12, plus aberrant
cell cycle progression13.
PARG, a single gene alternatively spliced to generate ﬁve iso-
forms, is an endo- and exo-glycohydrolase that rapidly degrades
PAR generated by PARP1 to coordinate DNA repair14,15. PARG
hydrolyzes α(1′′-2′) O-glycosidic linkages in PAR chains to release
ADP-ribose and oligo(ADP-ribose) chains that may signal geno-
toxic stress1. Bacterial, protozoan, and mammalian PARG struc-
tures16–21 reveal a macrodomain fold with conserved active site
residues and ‘tyrosine clasp’ (Tyr clasp) unique to PARG enzymes,
which suggest a common mechanism for PAR hydrolysis. However,
PARG does not cleave the terminal ADP-ribosyl group linked to the
target residue, which is turned over by macrodomain-containing
mono(ADP-ribose) (MAR) hydrolases22–24. Yet, deletion of all
PARG isoforms is embryonically lethal10, and deletion of the
nuclear isoform causes sensitivity to alkylating agents and ionizing
radiation (IR)25. PARG is recruited to DNA damage sites through
interaction with PCNA and PARP126, prevents IR-induced mitotic
catastrophe13 and maintains replication fork stability in a BRCA2-
dependent manner27. Conversely, PARG depletion can prevent
replication fork restart28. PARG genetic knockdown sensitizes var-
ious cancer cells to chemotherapeutic agents and radiation11,13,29,30
and may cause tumor-speciﬁc killing in BRCA2-deﬁcient cancer
cells27. Furthermore, reduced PARG activity can decrease cyto-
toxicity associated with inﬂammation, ischemia, and stroke3,31 and
reduces liver metastases of colon carcinoma32. PARG furthermore
regulates proliferation and differentiation of dendritic cells and
T cells via PARP/NF-κB in tumor metastases of colon carcinoma4.
Yet, PARG inhibition as a therapeutic strategy is directly questioned
by reports, showing that PARG downregulation enables PARPi
resistance in BRCA2 and p53-null mouse cell-line33, and that
PARG deﬁciency had little impact on BRCA1- and/or PTEN-
deﬁcient tumor cells34.
With these conﬂicting reports in mind, herein, we examined
the TCGA database and found that in most human cancers
PARG expression is upregulated, supporting the notion that
PARG enzymatic function is required for tumorigenesis35. We
sought to test PARG inhibition in cancer cells and found that
although existing PARG inhibitors (PARGi) have proven valu-
able29–31,36, issues with potency, bioavailability, rapid clearance,
selectivity, or deﬁned mechanism of action can cloud their
applications for biology. Reasoning that a bioavailable and spe-
ciﬁc PARG inhibitor would be an enabling tool, we employed
chemical library screening that led to the discovery of thio-xan-
thine/methylxanthine derivatives as bioavailable, potent and
speciﬁc PARG inhibitors. Our high-resolution crystal structures
of human PARG bound to these methylxanthine inhibitors
revealed detailed interactions that support a mechanism of
competitive inhibition. In particular, we ﬁnd that conformational
switching of the Tyr clasp that distinguishes PARG from MAR
and other glycohydrolases enables speciﬁc engagement of
methylxanthine derivatives in the PARG active site. Crucially, our
cell-based assays show effective cellular activity, including PAR
accumulation in cells, inhibited PARP1 dePARylation and
increased γH2AX foci formation. Indeed, H2AX phosphorylation
levels in cells treated with PARGi uncover synergistic sensitiza-
tion to IR. Furthermore, PARGi induces replication fork defects
resembling those reported with PARG knockdown36, and causes
cellular sensitivity in PARP1-inhibitor-resistant cells. Moreover,
our compounds are PARG-selective and do not target other
cellular glycohydrolases at the relevant doses, in contrast to other
reported PARGi’s. Our selective inhibitor reveals PARG functions
that support and extend previous genetic ﬁndings, providing
insights into PAR metabolism following IR damage and estab-
lishing these PARGi as enabling tools for investigating PAR
biology with potential for advanced therapeutic strategies.
Results
Identiﬁcation of speciﬁc PARG inhibitors. Our TCGA database
analysis revealed that in most human cancers PARG expression is
upregulated (Fig. 1a). Importantly, PARG enzymatic function can
be required for tumorigenesis35. Therefore, we sought to identify
a selective PARG inhibitor through our robust PARG enzyme
kinetic assay37, which quantitatively monitors real-time PAR-
mediated PARP1-XRCC1 interactions and disassembly in a
multi-well format. A strong TR-FRET signal was generated upon
assembly of the Tb3+-chelated XRCC1 (FRET donor) with
PARylated PARP1, which incorporates ﬂuorescein-labeled ADP-
ribose moieties into PAR chains (FRET acceptor). The addition of
PARG caused a time-dependent loss of the TR-FRET signal by
reversing PARylation and disassembling the PARP1-XRCC1
complex (Supplementary Fig. 1)37.
We screened the National Cancer Institute (NCI) Diversity Set
II library (1990 compounds) against rat PARG. Then, human
PARG was used to validate and optimize PARG inhibitors. The
accuracy of the screen was determined by the calculated Z-scores
of control reactions, which were between 0.6 and 0.8 throughout
the plates, indicative of high reproducibility (Supplementary
Fig. 2). Two different enzyme concentrations (12.5 nM and
25 nM) were used in subsequent analyses, with the rationale that
potent inhibitors would inhibit PARG activity at both enzyme
concentrations, while weaker inhibitors would inhibit PARG
activity only at the lowest PARG concentration. The rate of TR-
FRET signal loss in the presence of each candidate inhibitor was
compared to that of control reactions, containing DMSO only
(Fig. 1b). Initially, we selected 104 compounds that inhibited
PARG enzymatic activity at both enzyme concentrations. Thirty-
nine of these compounds were discarded as they altered
ﬂuorescence intensity of donor or acceptor (F520 and F495) by
>40% at the ﬁrst time point. An additional twelve compounds
containing metals (e.g., Pt, Hg, or As) and ﬁve compounds
resembling short chain fatty acids and steroids were also
discarded, leaving 51 candidate inhibitors (hit rate of 2.6%),
including 12 potent hits showing ~100% inhibition at both PARG
concentrations (Supplementary Table 1). For the selected
compounds, gel-based assays were performed to directly monitor
inhibition of PARP1 dePARylation by PARG (Fig. 1c).
Most initial hits from the High Throughput Screening (HTS)
contained 5- or 6-member rings and were grouped into ﬁve main
chemotypes (Supplementary Fig. 3): succinimide (JA1: 2 hits),
xanthine/methylxanthine (JA2: 13 hits), hydroquinone (JA3: 13
hits), nitrobenzofuranzan (JA4: 9 hits), and benzyl-sulfonamide
(JA5: 14 hits). A total of 34 compounds containing representative
hits and available analogues from each chemotype were then
analyzed in dose-response curves, using both the TR-FRET assay
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Fig. 1 Identiﬁcation of thio-xanthine/methylxanthine derivatives as PARG inhibitors. a PARG expression is upregulated in the majority of human cancers.
Analysis of PARG expression in TCGA tumors and matched normal tissues. Log p-values were from Wilcoxon tests with greater values indicating stronger
differences; PARG expression was higher in tumors than in matched controls in all tumor types (green) except in kidney malignancies (KIRC and KICH,
red). Datasets with >10 normal samples and signiﬁcant p-values were included. Box plots display the interquartile range (IQR) from Q1 to Q3 (25–75%
percentiles), median (centre line), whiskers extending to the minimum (Q1–1.5*IQR) and maximum (Q3+ 1.5*IQR) and outliers (dots). b the raw data
of HTS for JA2-3. The high reproducibility of the TR-FRET assay for PARG activity is reﬂected by a Z-factor of 0.6–0.8 (Supplementary Fig. 2), this
kinetic high-throughput screen was performed against the NCI Diversity Set II library (1990 compounds in seven 384-well plates) at 6.7 μM compound
concentrations and two PARG concentrations (12.5 nM and 25 nM). c Thio-xanthine/methylxanthine derivatives are potent PARG inhibitors. De-
PARylation of PARP1C by PARG (25 nM) in the presence of the designated compound at 6.7 μM (left panel); the structure of the chemicals (right panel),
among ﬁve chemotypes identiﬁed from the HTS (Supplementary Fig. 3). The JA2 xanthine/methylxanthine series was selected as the lead pharmacophore,
based on its structural similarities to adenine, potency in vitro, and favorable drug-like characteristics. Dose-dependent inhibition of PARG activity by the
JA2 series compounds was quantitatively analyzed using a gel-based PARG activity assay (Supplementary Fig. 4). d Three representative HTS hits of the
JA2 chemotype (JA2-3, JA2-4, and JA2-5) show a potent PARG inhibition with the sub-micromolar range of IC50 values. Source Data are provided as a
Source Data ﬁle.
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and the gel-based assay. We conﬁrmed that 19 compounds from
ﬁve chemotypes inhibit PARG activity at concentrations of
0.1–10 μM (Supplementary Fig. 4 and Supplementary Table 2).
The TR-FRET assay is an indirect measurement of PARG
activity, as it monitors PARG-mediated reversal of a PAR-
dependent PARP1-XRCC1 interaction. Furthermore, loss of the
TR-FRET signal was not detected until all PAR chains were
degraded to lengths shorter than 7 ADP-ribose units37. None-
theless, this assay enabled the measurement of steady-state PAR
turnover rate, which was adequate for detecting enzyme
inhibitors. In contrast, the gel-based assay directly monitors
enzymatic conversion of PARylated PARP1 to an unmodiﬁed
product by PARG, enabling a semi-quantitative measurement of
enzyme inhibition (Supplementary Fig. 4). The IC50 value of a
known PARG inhibitor, adenosine diphosphate (hydroxymethyl)
pyrrolidinediol (ADP-HPD), determined by the gel-based assay
(1.07 μM, Supplementary Fig. 5), which was in agreement with its
published values (0.1–1.4 μM)20,38,39. Therefore, we chose the gel-
based PARG activity assay in subsequent studies.
Inspection of the ﬁve identiﬁed chemotypes of PARG
inhibitors (Supplementary Fig. 3) suggests that the JA2 series of
xanthine/methylxanthine derivatives were the most attractive for
several reasons. First, these compounds are structurally analogous
to the adenine base of ADP-ribose (ADPR), an enzymatic
product of PARG and have good potential for site-speciﬁc
binding. Second, xanthine/methylxanthine-based compounds
typically show good bioavailability, as evidenced by caffeine and
the widely used bronchodilator, theophylline40. Third, the fused
5- and 6-membered rings of the xanthine core are synthetically
tractable for analoging40. Most importantly, three thio-xanthine/
methylxanthine derivatives (JA2-3/NSC29192, JA2-4/NSC99657,
and JA2-5/NSC99667) were among the most potent dose-
dependent inhibitors of PARG activity as assessed by HTS, with
IC50 values between 0.1 and 1.0 μM (Fig. 1d).
JA2-4 speciﬁcally binds to the hPARG adenine-binding pocket.
To identify the binding sites of JA2-3, JA2-4, and JA2-5, these
compounds were soaked into crystals of human PARG (hPARG)
catalytic domain (residues 448–976). Crystals of hPARG dif-
fracted to high resolution, and the crystal packing arrangement
was more amenable to binding compounds in the enzyme active
site20, compared to crystals of rat and mouse PARG18,19. The
hPARG active site has two deep pockets that speciﬁcally engage
the adenine and diphosphate group of ADPR. Tyr795 at the tip of
the Tyr clasp points towards the heart of the active site and
simultaneously interacts with the adenine and diphosphate
moieties.
The crystal structure of JA2-4 bound to hPARG reﬁned at
1.7 Å resolution, (Fig. 2 and Supplementary Tables 3) identiﬁed a
single JA2-4 molecule in the adenine-binding pocket. The
6´-thiocarbonyl sulfur of JA2-4 was assigned by the size and
orientation of the electron density compared to that of the
corresponding 6´-carbonyl oxygen of JA2120 (Figs. 2a and 3b).
JA2-4 makes extensive site-speciﬁc interactions with hPARG,
consistent with its potent inhibitory activity (IC50 of 0.9 μM)
(Fig. 1d). The methylxanthine head of JA2-4 makes π-stacking
interactions with Phe902 side chain. The tail of JA2-4 extends
from the 8´-position of the xanthine ring and is highly curved,
which serves to make van der Waals contacts with Asn869. The
terminal pyrrole of JA2-4 is rotated ~90° and is perpendicular to
the xanthine ring system. Importantly, most protein-JA2-4
interactions come from the conserved macrodomain fold. Despite
the large conformational change (described below), the Tyr clasp
generates limited direct contact with JA2-4; only the Cβ of Tyr795
interacts with the thioether group of JA2-4 (Fig. 2a). JA2-4 has a
surface area of 484 Å2 of which 89% (432 Å2) is masked by direct
contacts with hPARG, which can explain the relatively high
potency of the JA2-4 series compounds.
Structural superposition of hPARG bound to JA2-4 and ADP-
HPD revealed that the methylxanthine core of JA2-4 occupies the
same binding site as the adenine of ADP-HPD (Fig. 2b),
consistent with a competitive block of substrate binding activity.
However, the ring system of the xanthine core is ﬂipped
horizontally and rotated ~15° clockwise, relative to the adenine
ring of ADP-HPD, and translated 0.8 Å towards the tip of the Tyr
clasp. This distinctive ring orientation reﬂects a direct interaction
of the 6´-thiocarbonyl group with the main chain amide of
Asn869 (Fig. 2a). As predicted, a thiol substituent at the 6´
position of the methylxanthine pharmacophore greatly increases
potency (Fig. 3). Additionally, the 2´-carbonyl oxygen of JA2-4
hydrogen bonded with the main chain amide of Ile726. This
interaction is not made by ADP-HPD, and it displaces the
methylxanthine ring by 0.8 Å with respect to the adenine ring of
ADP-HPD (Fig. 2a, b). The 2´-carbonyl oxygen of JA2-4 also
serves as a pivot point for rotation of the methylxanthine ring.
Collectively, these structures support speciﬁc and potent inhibi-
tion of PARG activity by JA2-4 and suggest a mechanism of
competitive inhibition by JA2 series xanthine/methylxanthine
derivatives.
Identiﬁcation of key contact points of JA2-4. The most striking
feature of the JA2-4 interaction with hPARG is a signiﬁcant
change in the Tyr clasp conformation (Fig. 2c). The JA2-4
binding site is obstructed by the side chain of Tyr795 in the
unbound hPARG and in hPARG bound to ADP-HPD. To
accommodate JA2-4, the Tyr795 side chain is ﬂipped out
from the adenine-binding pocket (with ~90° rotation), which
positions the thioether of JA2-4 in contact with Cβ of Tyr795.
Furthermore, the interaction of JA2-4 with Tyr795 pushes on the
tip of the Tyr clasp, which is displaced ~0.9 Å towards the N-
terminal helical bundle (Fig. 2c).
Twisting of the Tyr clasp induced by JA2-4 binding involves
several new interactions with a neighboring helix α6 (Fig. 2c).
Most notably, JA2-4 binding caused the Arg671 side chain to
swing ~9 Å towards the tip of the Tyr clasp, where it makes an
electrostatic interaction with Glu797 side chain and hydrogen
bonds to the main chain carbonyl of Ala750 (not shown in this
view). This Arg671 pivoting motion constitutes a switch that
serves as a backstop to secure the Tyr clasp in contact with the
N-terminal helical bundle, which is ~30 Å away from Tyr795.
Taken together, this previously undetected structural switching of
the Tyr clasp may explain the basis of JA2-4 binding and its
inhibition of PARG activity.
Structure-based design improved PARGi potency and
selectivity. We examined the structure-activity relationships (SAR)
of JA2-4 analogs (Fig. 3) in competitive inhibition experiments.
JA2131/NSC98003 contains a terminal morpholine in place of the
pyrrole of JA2-4 and shows improved activity, which may derive
from a polar interaction mediated by the 1´-oxygen of the mor-
pholine (Fig. 3a, c). The 6´-thiocarbonyl group of JA2131 is another
driver of inhibitory potency. Substitution with a carbonyl at this
position decreases potency more than 50-fold (IC50 of JA2131=
0.4 μM, IC50 of JA2120/NSC81474= 25.7 μM, Fig. 3c), even though
the 6´-carbonyl oxygen of the methylxanthine of JA2120 can make
a hydrogen bond with the main chain amide of Asn869. The
position of the thiocarbonyl group can be changed without the loss
of activity because JA2131 (6´-thiocarbonyl; IC50 of 0.4 μM)
(Fig. 2c) and JA2-5 (2´-thiocarbonyl; IC50 of 1.0 μM) (Fig. 1d)
exhibit comparable potencies.
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To further test the molecular basis for these SAR data, crystal
structures of hPARG bound to JA2131 and JA2120 were
determined at 1.9 and 1.8 Å resolution, respectively (Fig. 3a, b).
JA2131 and JA2120 bind to the adenine-binding pocket of
hPARG in the same orientation as JA2-4. As for JA2-4, the
6´-thiocarbonyl of JA2131 makes a direct van der Waals contact
with the main chain amide of Asn869 (3.6 Å) from the conserved
macrodomain fold (Fig. 3a). The morpholine oxygen of JA2131
appears to accept a hydrogen from the side chain amine of
Asn869, explaining the modest increase in potency compared to
JA2-4 (Fig. 2a).
In contrast, the distance between 6´-carbonyl of JA2120 and
the main chain amide of Asn869 is signiﬁcantly longer than that
of 6´-thiocarbonyl of JA2131 and is beyond the range of direct
polar or van der Waals interactions (4.3 Å) (Fig. 3b). Instead, a
bound water molecule, which is absent in the JA2131- and JA2-4-
bound structures, is positioned between JA2120 and Asn869.
The bound water molecule relays an indirect hydrogen bond from
6´-carbonyl of JA2120 to the main chain amide of Asn869 and to
the main chain carbonyl of Phe902 (Fig. 3b). A bound water
molecule is also present at this site in structures of hPARG and
hPARG bound to ADP-HPD. Notably, the 6´-thiocarbonyl
group of JA2-4 series inhibitors displaces this water molecule to
form improved interactions with the adenine-binding pocket
of hPARG.
PARG regulates PARP1 modiﬁcation in cells. To identify sui-
table cell lines to test PARGi, we evaluated PARG protein
expression patterns on a panel of prototypic cancer cell lines.
Cells were fractionated into cytoplasmic, nuclear and chromatin,
and then PARG expression and localization were evaluated using
an anti-PARG antibody (Fig. 4a). A varying level of PARG was
detected in three cellular compartments. In prostate adenocarci-
noma (PC3) and breast mammary epithelial (MCF-7) cells,
PARG level was the highest in the cytoplasm, followed by
the nucleus, with the lowest seen in the chromatin fraction. The
triple-negative MDA-MB-231 breast cancer and U2OS osteo-
sarcoma cells showed comparable expression between cytoplasm
and nucleus. The PC3 cell line, with one of the highest levels of
PARG expression, was selected for our initial PARGi testing. PC3
cells were treated with either DMSO or JA2131 for 2 h, then
exposed to 7 Gy of IR and allowed to recover for a designated
time period before harvesting and cell fractionation. Chromatin
fractions of the cell lysates were analyzed by immunoblotting with
PARP1 speciﬁc antibody (Fig. 4b), and the PARylation states of
PARP1 were monitored as a marker for PARG inhibition. A high
molecular weight (HMW) PARP1-containing band in the chro-
matin fractions, suggestive of hyper-PARylated PARP1, was only
seen in cells treated with JA2131 PARGi. Cells treated with both
JA2131 and IR displayed enhanced levels of PARylation-trapped
PARP1 (Fig. 4b, 0.5 h versus 1.0 h). In these cells, PARylated
PARP1 in response to PARG inhibition appeared as a discrete
HMW (DHMW) proteins with limited smearing, as observed
previously41. The DHMW was only seen when chromatin frac-
tions were immunoblotted with the PARP1 antibody; by contrast,
nuclear fractions and total cell lysates showed a contiguous
smear, typically associated with PARylated PARP1. To assess
whether DHMW was due to PARylation and not any other






























Fig. 2 JA2-4 binds to the adenine-binding pocket of hPARG by virtue of the ﬂexibility of the Tyr clasp. a 1.7 Å crystal structure of human PARG bound to
JA2-4 reveals speciﬁc and extensive inhibitor interactions with the adenine-binding pocket. The 6´-thiocarbonyl sulfur of JA2-4 was assigned by comparing
the size and orientation of the electron density to that of the corresponding 6´-carbonyl oxygen of JA2120 (Fig. 3b). JA2-4 is shown with a Fo-Fc map
(contoured at 2σ) that was calculated prior to the addition of JA2-4 to the model. JA2-4 bound PARG catalytic domain shown in the enlarged box. b A
structural comparison of the binding interactions of JA2-4 and ADP-HPD is consistent with a competitive inhibition mechanism for JA2-4. The structure of
hPARG bound to ADP-HPD (wheat) is overlaid onto that bound to JA2-4 (white). The methylxanthine core of JA2-4 makes extensive interactions and
occupies the same binding site as the adenosine moiety of ADP-HPD and. c The Tyr clasp changes conformation to enable binding of JA2-4. JA2-4 binding
shifts the position of the Tyr clasp in concert with the rotation of the Tyr795 side chain and rearrangement of Arg671. The structural ﬂexibility of the Tyr
clasp creates room for JA2-4 and facilitates interactions with Asn869 and I726 that contribute to potent inhibition of PARG activity (IC50 of 0.9 μM).PDB
code: 6O9X (PARG/JA2-4), 6O9Y (PARG/JA2-8), 6OA0 (PARG/JA2-9).
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PARGi-treated PC3 cell-lysates were treated with puriﬁed PARG,
followed by anti-PARP1 western blotting. This led to the
restoration of LMW PARP1, indicating PARylation was indeed
causing the DHMW (Fig. 4c, d). Thus, a dynamic equilibrium
between DHMW and LMW nuclear PARP1 exists in cells, and
PARGi shifts this equilibrium towards DHMW. We conclude that
PARGi induces PARP1 DHMW as a result of persistent PAR-
ylation, which can be reversed in vitro with exogenous puriﬁed
PARG, suggesting a selective role of PARG in the dynamic reg-
ulation of PARP1 modiﬁcation and signaling.
PARGi induces PAR accumulation and γH2AX foci in nuclei.
As we found that inhibition of PARG increases PARP1 in a
PARylated DHMW form, we tested whether our PARGi aug-
ments the level of PAR accumulation and of double-stranded
DNA (dsDNA) breaks in cells treated with IR. Following IR, cells
treated with JA2131 showed a signiﬁcant increase in PAR accu-
mulation in comparison to untreated cells (20-fold increase with
JA2131). DMSO treated cells showed a modest post-IR
PAR accumulation that was comparable to the untreated cells
(Fig. 5a, b, DMSO versus JA2131). A low magniﬁcation 3 × 3
image montage showed distinct PAR accumulation and γH2AX
foci formation (Fig. 5a and Supplementary Fig. 6). Quantiﬁcation
revealed that PAR accumulation coincides with γH2AX staining
and foci formation, which was >10-fold higher in PARGi-treated
cells than in control cells (Fig. 5c). Furthermore, at least 50% of
cells showed colocalization of PAR and γH2AX foci (Fig. 5d,
γH2AX/PAR foci against total cell counts Fig. 5e). Western blot
analyses also indicated that JA2131-induced PAR accumulation
(Fig. 5f). Inspection of images at high magniﬁcation validates
the automated quantiﬁcation of observed JA2131-induced
PAR/γH2AX colocalization. DMSO treated cells display diffuse,
low-level PAR staining in the nucleus of cells with limited γH2AX
foci. However, for cells treated with the PARGi JA2131, PAR
staining was localized to distinct nuclear foci that also contained
the phosphorylated H2AX (γH2AX) (Fig. 5g). We saw some
γH2AX foci in DMSO treated cells, but only if the contrast was
independently adjusted (see Supplementary Fig. 6a, b, bottom
panels). Indeed, PAR accumulation caused by the treatment of
cells with IR was further augmented by the PARGi, indicating
that it functions as a DNA damage sensitizer. It was previously
reported that genetic knockdown of PARG results in sensitization
of cancer cells to chemotherapeutic agents and radiation11,13,29,30,
and tumor-speciﬁc killing in BRCA2-deﬁcient cancer cells27.
Here, we reveal an effective PAR accumulation that coincides
with elevated γH2AX following treatment with a novel PARGi in
PC3 cells that have intact BRCA1 and BRCA2 genes42.
JA2131 kills cancer cells through selective PARG inhibition. To
determine the radiation sensitization effect of PARGi, a clono-
genic cell survival assay was used to measure radiation sensiti-
zation in PC3, MDA-MB-231, and MCF-7 cell lines treated with
JA2131. First, we deﬁned the radiation dose response and the
optimum cell plating number for each cell-line (Supplementary
Fig. 7). Secondly, DMSO and the PARPi Olaparib were used as a
negative and positive control respectively (Supplementary Fig. 8).
The results show that PARG inhibitor JA2131 inhibits colony
formation in all three cell lines. MCF-7 cells were less sensitive to
JA2131 than the PC3 cells. The triple-negative breast cancer cells
MDA-MB-231 were the most sensitive among the three cell-lines
treated with JA2131 (Fig. 6a). Interestingly, in MCF-7 cells with
the highest level of cytoplasmic PARG showed greatest sensitivity
to the commercially available PARGi PDD00017273 (PDD

























































Fig. 3 The 6´-thiocarbonyl group contributes strongly to the potency. a, b Crystal structures of human PARG bound to JA2131 a and JA2120 b. JA2131 and
JA2120 occupy the adenine-binding pocket of hPARG in the same orientation as JA2-4. The 6´-thiocarbonyl of JA2131 makes a direct van der Waals
contact with the main chain amide of Asn869 (3.6 Å) a, whereas the 6´-carbonyl of the less potent inhibitor JA2120 makes water-mediated hydrogen
bonds to the main chain amide of Asn869 (4.3 Å) and the main chain carbonyl of Phe902 b. These ﬁndings indicate that the 6´-thiocarbonyl group of JA2-
4 series inhibitors increases potency by introducing a direct interaction with hPARG. c The structure-activity relationships (SAR) for JA2-4 series inhibitors.
The direct interaction between the 6´-thiocarbonyl group of JA2131 and hPARG increases potency more than 50-fold in comparison to JA2120. PDB code:
6OA1 (PARG/JA2120), 6OA3 (PARG/JA2131). Source Data are provided as a Source Data ﬁle.
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underlying genetic variations that dictate PARG protein expres-
sion patterns and signaling could play an important role in the
effectiveness of PARGi with implications for vetting future
PARGi patient groups. In addition, we tested the effect of sus-
tained JA2131 treatment alone or in combination with IR in
colony formation. Indeed, JA2131 alone was sufﬁcient to inhibit
PC3 survival, but when combined with IR was more effective in
reducing the number of surviving cell-colonies (Supplementary
Fig. 9).
The triple-negative breast cancer cells MDA-MB-231 showed
the largest response in our clonogenic survival assay (Fig. 6a).
Thus, dose-dependent JA2131-induced cellular PARylation with
and without IR was investigated. For combined IR treatment,
MDA-MB-231 cells were treated with JA2131 for 2 h, followed by
7 Gy X-ray and then allowed to recover for an hour before cellular
extraction and western blotting analysis. PARGi-treated cells
alone showed a dose-dependent increase in cellular PARylation
between 1 μM and 5 μM doses. However, PARGi combined with
IR induced a massive increase in cellular PARylation at 100 nM
(Fig. 6b). Notably, cells treated with radiation alone (Fig. 6b, lane
1) or inhibitor alone (Fig. 6b, lanes 2–5) did not show the level of
PARylation observed when both treatments were combined,
(Fig. 6b, lane 7–10) suggesting a synergistic, rather than an
additive effect.
Using shRNA, next, we generated a stable MDA-MB-231
PARG knockdown (PARG-KD) cell-line (Supplementary Fig. 10).
We compared PARGi JA2131-induced PARylation in PARG-KD
and control cells. We reasoned that PARG-KD cells would show a
reduced response to a selective PARGi as the stable PARG-KD
cells would have to adopt a PARG-independent survival
mechanism. MDA-MB-231 control cells and PARG-KD cells
were treated with JA2131, then total cell lysates were subjected to
immunoblotting with anti-PAR antibody, followed by immuno-
detection for anti-PARG, PARP1 and Actin antibody (Fig. 6c). As
expected, untreated PARG-KD cells showed a higher baseline
level of PARylation than the control cells. Treatment with JA2131
did not affect the level of PAR accumulation in PARG-KD cells;
whereas, a measurable increase in PAR was seen in the MDA-
MB-231 cells. Treatment of the cells under the same inhibitor
regime with IR showed equivalent results (see Supplementary
Fig. 11). Dose-response curves comparing control and PARG-KD
cells further validate the selective action of JA2131 on control
cells expressing PARG, but not on the PARG-KD cells
(Supplementary Fig. 12). As a comparison, we also tested the
inhibitor PDD, which induced PARylation in both control and
PARG-KD cells. However, both cell-lines responded with
increased PARylation from the PDD inhibitor, suggesting
potential non-selectivity towards other cellular glycohydrolase
(Supplementary Fig. 13).
To further evaluate the selectivity of JA2131, we performed
Sulforhodamine B (SRB)43 cytotoxicity tests in MDA-MB-231
control and PARG-KD cells (Fig. 6d). The results show
approximately a 10-fold higher IC50 value for PARG-depleted
cells, compared to control cells with a normal level of PARG (see
Fig. 6d, IC50 table). Notably, only 50% of the PARG-KD cells
responded to the PARGi to produce the indicated IC50. In
DMSO JA2131
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Fig. 4 JA2131 induces hyperPARylation of PARP1. a Subcellular PARG protein expression patterns in cultured cells. Subcellular fractionated lysates were
immunoblotted with anti-PARG, (upper panel) followed by nuclear (N) marker anti- Laminin Subunit Beta 1 (LAMB1, upper middle panel), chromatin (Chr)
marker anti-Histone H3 (H3, lower middle panel) and the cytoplasmic (C) marker anti- Glyceraldehyde 3-phosphate dehydrogenase (GAPDH, lower panel)
b PC3 cells were treated with DMSO or PARG inhibitor JA2131 (2131) for 2 h then irradiated with 7 Gy and allowed to recover for 0.5 h or 1.0 h before lysis
and subcellular fractionation. Chromatin bound cell-extracts were analyzed with anti-PARP1 antibody (upper panel) followed by probing with total Histone
H2AX (t-H2AX, lower panel) as the loading control. c DMSO or 2131-treated PC3 cells were irradiated and recovered for 2 h as above, chromatin fractions
were then incubated with or without puriﬁed PARG enzyme (±PARG) for 30min at 37 °C then immunoblotted with anti-PARP1 (upper panel) and then with
anti-histone H3 (lower panel) as loading control. d Quantitative analysis of western blot of b, where expression of PARP1 levels in DMSO treated was
normalized to 1. High molecular weight (HMW) in red PARP1 is signiﬁcantly decreased in the presence of puriﬁed truncated PARG protein. The low
molecular weight in black PARP1 bands are not signiﬁcantly affected, n= 3. Plus denotes added puriﬁed PARG enzyme. Source Data are provided as a
Source Data ﬁle.
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addition, we used normal human lung ﬁbroblast cell-line MRC-5
to determine whether JA2131 exhibits speciﬁcity towards cancer
cells. Our results show that the cytotoxic dose of JA2131 in MRC-
5 cells is an order of magnitude higher than that seen for MDA-
MB-231 cells (Fig. 6e, IC50 table). Doxorubicin and PARPi
Veliparib were used as a positive and negative control,
respectively. Thus, our collective cytotoxicity data show that
JA2131 indeed acts through inhibition of PARG and that it
selectively kills cancer cells. To further validate the inhibition of
PARG in cells by JA2131, we performed the cellular thermal shift
















































































































Fig. 5 PARGi sensitizes cells to IR damage. a High level of PAR accumulation and γH2AX foci formation in cells exposed to PARGi. PC3 cells treated with DMSO
or PARG inhibitors (JA2120 or JA2131) for 2 h, irradiated with 7 Gy, recovered for 1 h were ﬁxed and immuno-stained with Poly(ADP)-Ribose (PAR, green) and
γH2AX (red) antibodies, nucleus stained with Hoechst (blue). Cells were analyzed with quantitative high-content imaging (b–e). Quantitative analysis of PAR
intensity (b), γH2AX intensities (c), the number of cells showing PAR / γH2AX co-localizations (d), and nucleus count for the total number of cells analyzed for
each group (e). f Immunoblotting of PARGi JA2131-treated PC3 cells showing inhibitor-induced cellular PARylation. Cells were treated with JA2131 for 2 h
followed by 7Gy IR, then allowed to recover for 1 h before lysis. Total cell lysates were immunoblotted with anti-PAR (upper panel) followed by anti-PARG
(middle panel) and Anti-PCNA (lower panel) as loading controls. g Enlarged, individual, representative images taken from one quadrant of the 3 × (3 × 3) square
shown in a and the region marked with an asterisk. This represents the quality of the image used to perform quantiﬁcation for foci and colocalization
calculations. Anti-PAR (green), Anti-γH2AX (red) and Hoechst 33342 (blue). Scale bar 25 μm. Note that the image contrast was quantitatively controlled and
equal for both sets of data, see Supplementary Fig. 6 for independently contrast-adjusted images. Source Data are provided as a Source Data ﬁle.
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assay (CETSA)44 on PC3 cells treated with either DMSO or
JA2131. The results show JA2131 treatment induced a 9 °C
stabilization of PARG proteins in cells (Fig. 6f and Supplementary
Fig. 14); whereas, the PCNA control showed no signiﬁcant
change in thermal stability in response to JA2131 treatment
(see Fig. 6f).
We also evaluated JA2131’s speciﬁcity in vitro as an inhibitor
of puriﬁed hPARG in the presence and absence of detergent
(Triton-X 100, 0.1%) or a nonspeciﬁc target protein (bovine
serum albumin BSA, 0.1 mg/ml). This concentration of Triton-X
100 is ~10-fold higher than its critical micelle concentration
(CMC, 0.0155%), so it can effectively distinguish promiscuous
and aggregating compounds45. Neither the addition of Triton-X
100 nor BSA signiﬁcantly altered the inhibitory potency of
JA2131 (Supplementary Fig. 15a). In addition, we also examined
whether or not JA2131 could nonspeciﬁcally interfere with
PARP1 activation. PARP1 is an abundant nuclear enzyme and
PARylated PARP1 is an abundant substrate for PARG, following
DNA damage. JA2131 did not inhibit PARP1 activation up to
100 μM; whereas, a potent PARP inhibitor Olaparib completely
shuts down PAR synthesis by PARP1 (Supplementary Fig. 15b).
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interactions between JA2131 and its binding site on hPARG
(Fig. 3), support the conclusion that JA2131 selectively inhibits
PARG activity.
JA2131 causes replication fork defects. In the BRCA2-negative
background, the depletion of PARG inhibits cell growth27. Yet,
we ﬁnd that PC3 cells with intact BRCA2 show exquisite DNA
damage induction by JA2131 as seen by γH2AX foci formation
(Fig. 5) and poor long-term survival (Fig. 6a). Therefore, we
investigated if this JA2131-induced massive γH2AX foci forma-
tion leads to growth arrest and cell death. JA2131-induced cel-
lular cytotoxicity in PC3 cells with or without IR, along with
commonly used DNA damaging agents and the chemother-
apeutic agents Doxorubicin and Nedaplatin (Fig. 7a, inset table).
Surprisingly, there was no added beneﬁt for combining PARGi
with IR, in fact, cells actually survived slightly better in this 72 h
assay period (see Fig. 7a, IC50 table). This is contrary to long-term
clonogenic survival (Fig. 6a) and massive γH2AX foci formation
(Fig. 5c) observed with combined PARGi and IR treatment.
Indeed, we also observed a similar phenomenon with Olaparib-
treated PC3 cells, where IR induced higher IC50 values compared
to the non-IR treated samples (see Supplementary Fig. 16).
Therefore, we reasoned that IR exposure activates homology-
directed repair (HDR), which counteracts PARGi effects in the
short term. However, PARGi-treated dividing cells accumulate
damage from replication stress over time that decreases long-term
survival as observed in clonogenic assays.
Furthermore, we tested our inhibitors in A172 glioblastoma
cells that are resistant to PARPi and platinum-based chemother-
apeutic agents. Cellular cytotoxicity assay showed our PARGi was
more effective than Veliparib, but comparable in potency to
Nedaplatin (Fig. 7b, inset IC50 table), indicating another cancer
where PARGi could play an important therapeutic solution.
Recently, PARG depletion was shown to cause recruitment of
double-strand-break-repair factors to chromatin in the absence
damage and to slow replication fork progression,36 consistent
with PARG function in replication stress protection through the
resolution of dysfunctional replication-structures. Because our
PARGi effectively killed cancer cells in the absence of DNA
damage (Fig. 6d, Fig. 7a, b), we reasoned that JA2131 could be
acting at the replication fork. Therefore, we tested whether our
PARGi could induce replication stress defects. HeLa cells
pretreated with JA2131 or DMSO for 2 h were used to evaluate
fork progression in DNA ﬁber assay (Fig. 7c, d). Indeed, PARGi
alone was sufﬁcient to induce a signiﬁcant reduction in
replication progression in the absence of genotoxic stress. Under
these conditions, PARGi induced a statistically signiﬁcant
reduction in the average IdU tract from 7.5 to 6.0 μm. Thus, we
tested replication progression in the presence of mild genotoxic
stress delivered by a low-dose of hydroxyurea (Fig. 7e, f). Under
this mild genotoxic stress-condition, we observed a reduction
in the average IdU tract length to 5.0 μm. These ﬁndings
show that our PARGi recapitulates reported replication defects
caused by PARG depletion36, a ﬁnding that further validates
JA2131 selective action against PARG.
Discussion
Reversible PARylation at DNA breaks and replication forks
enforce control of modular assemblies of dynamic complexes,
enabling damage detection, signaling, compartmental localiza-
tion, and repair46,47. The ability to control PARylation reversal by
PAR glycohydrolases48 particularly PARG, which is the pre-
dominant enzyme that removes PAR chains at sites of DNA
damage12,49 offers the potential to control uniquely susceptible
damage responses in cancer cells. Yet, there is no PARGi in the
clinic, and existing inhibitors show various limitations. A classic
PARG inhibitor is Gallotannin (GT), a large naturally occurring
polyphenol that exhibits inhibition of PARG with an IC50 below
5 μM50. GT retards DNA repair51, protects against H2O2-medi-
ated cell death50, sensitizes cancer cells to Cisplatin52, and can
speciﬁcally kill BRCA-deﬁcient breast cancer cells27. However,
concerns exist about GT’s possible nonspeciﬁc mode of action
and membrane permeability, as well as its antioxidant activity53.
Salicylanilide derivatives appear to be nonspeciﬁc PARG inhibi-
tors45. Rhodanine-based PARG inhibitors (RBPIs) are selective
PARG inhibitors in vitro with low micromolar potency, but their
bioavailability and cellular activity remain questionable45. Qui-
nazolinedione sulfonamide derivatives target the PARG active
site; however, rapid clearance in vivo renders them unsuitable as
therapeutic agents54. The recently reported small-molecule
PARGi PDD54 has strong effects on cellular PAR metabolism.
Yet, our tests with PARG-depleted cells suggest a nonspeciﬁc
mode of PDD action in mammalian cells. Such concerns with
existing inhibitors motivated the efforts presented here for the
development of a pharmacologically viable and selective PARGi
via chemical library screening and structure-based drug design to
improve potency and selectivity. These efforts led to the identi-
ﬁcation of thioxanthine/methylxanthine derivatives as chemically
tractable and reasonably potent pharmacophores for speciﬁc and
cell-permeable chemical knockdown of PARG (Fig. 1), for testing
PARG biological functions and for therapeutic potential. Notably,
methylxanthine derivatives occur in many plants and are among
Fig. 6 Selective inhibition of PARG by xanthine derivative JA2131. a Clonogenic survival assays of PC3, MDA-MB-231, and MCF-7 cells treated with PARGi.
Cells were treated with either DMSO or 10 µM JA2131 for 2 h, irradiated with 3 Gy (MDA-MB-231 and MCF-7), 7 Gy (PC3) IR and grown for ~2 weeks, then
colonies were ﬁxed with methanol and stained with crystal violet. The results of three independent experiments are shown. Error bars= the standard error
of the mean (SEM). b dose-response of JA2131 in MDA-MB-231 cells with and without IR. Cells were treated with designated concentrations of JA2131 for
2 h and then either left untreated or exposed to 3 Gy IR and allowed to recover for 1 h before lysis. Total protein was immunoblotted with anti-PAR antibody
(upper panel), stripped and reprobed with anti-PCNA as a loading control. c MDA-MB-231 cells with stable scrambled shRNA (WT) or stable PARG
shRNA, knockdown (KD), were treated with 5 μM JA2131 for 2 h, lysed and then total lysates were immunoblotted for anti-PAR (upper panel) followed by
anti-PARG (upper middle panel), anti-PARP1 (lower middle panel) and anti-actin (bottom panel) antibody. Numbers on the blot shows relative band
intensities determined by ImageJ. d The SRB cytotoxicity assay to evaluate JA2131 in MDA-MB-231 cells. Stable cells with scramble shRNA (control) and
shPARG (PARG-KD) cells were treated with an increasing concentration of JA2131 for growth inhibitory IC50 determination. The data was normalized
against 100% survival at the lowest inhibitor concentration. Graphs for IC50 were ﬁtted to the four-parameter logistic equation using Prism8 and shown in
the table (see methods). Error bars show the percent coefﬁcient of variation. Equivalent concentrations of DMSO were used as a negative control. e The
cytotoxicity of JA2131 along with PDD, Veliparib and Doxorubicin against MRC-5 cells. The IC50 curves were generated as described above and shown in
the table. Error bars show the percent coefﬁcient of variation. f CETSA for in-cell JA2131 target engagement. Normalized anti-PARG western blot intensities
of three independent experiments were ﬁtted as above and the estimated aggregation temperature (Tagg) is shown in the tabulated insert. Source Data are
provided as a Source Data ﬁle.
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the most broadly consumed of all pharmacologically active
compounds40.
The active JA2-4 series compounds (JA2-4 and JA2131)
identiﬁed here display multiple complementary features and
speciﬁc interactions with the hPARG active site, consistent with
the observed sub-micromolar IC50. These PARGi are small in
comparison to most drugs, so they provide suitable prototypes
that suggest sites for modiﬁcations to improve potency and
pharmacokinetic properties. Our current structural data further-
more reveals the molecular bases of the speciﬁc and competitive
PARG inhibition by thio-methylxanthine derivatives (Figs. 2, 3).
From the protein-ligand interactions identiﬁed here, the 6´-thio-
methylxanthine derivatives JA2-4 and JA2131 compete with the
adenine moiety of PAR substrates for active site binding.
Moreover, our structures unveil how the hPARG Tyr clasp
switches between two conformational states to speciﬁcally engage
methylxanthine derivatives containing different functional
groups. This structural plasticity of the Tyr clasp is a key feature
accompanying the binding of the potent JA2-4 series inhibitors.
The Tyr clasp is a unique feature of PARG that is absent in other
PAR glycohydrolase macrodomains, such as ARH355, suggesting
why PARG-KD cells show speciﬁc PARG inhibition by JA2131
(Fig. 3). A similar strategy of anchored plasticity to induce
changes by inhibitor binding, allowed the design of potent
selective inhibitors of nitric oxide synthases56, supporting the
value of this inhibitor type for PARG.
Importantly, identiﬁcation and characterization of JA2131 as a
selective PARGi enabled direct examination of PARG signaling
and the nature of PARP1-PARG relationship in DNA damage
responses in cells. Notably, PARP1 is both the main polymerase
and acceptor of PAR in response to DNA damage. Our data
reveal that PARGi trapped PARP1 in a PARylated form (Fig. 4b).
DePARylated PARP1 showed a single step change in molecular
weight that suggests a potent glycohydrolase with a fast PAR
turnover rate for alleviating PARP inhibition imposed by
autoPARylation at the DNA damage site. Indeed, this idea is
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Fig. 7 Cytotoxicity and fork stalling induced by PARGi. a Cytotoxicity of PC3 cells for the indicated compounds with or without 7 Gy IR for 72 h treatment
periods. Normalized % viabilities are plotted against log concentration. Error bars show the percent coefﬁcient of variation. The data table shows IC50
values for each compound. b Comparisons of the relative cytotoxicity of JA2131 against the designated DNA damaging agents for A172 glioblastoma cells.
Treatment period 72 h. c A schematic of the dual-labeling regime used for the replication fork progression DNA ﬁber assay and representative DNA ﬁber
images of the replication tract from DMSO and JA2131 treated HeLa cells. Scale bar 5 μm. d Quantiﬁcation of the IdU tract analysis for more than 380
replication forks. e Schematic representation of HU (0.4 μM) treatment for fork progression analysis and the representative DNA ﬁber image of replication
tracts of DMSO and JA2131 treated HeLa cells. Scale bar 5 μm. f Quantiﬁcation of the IdU track of more than 470 replication forks for each data group.
Mann-Whitney test was used to generate the p-value. The DNA spread assay is the representation of two independently repeated experiments. Source
Data are provided as a Source Data ﬁle.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13508-4 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:5654 | https://doi.org/10.1038/s41467-019-13508-4 | www.nature.com/naturecommunications 11
PARG inhibition as a therapeutic option is directly questioned
by a report showing PARG downregulation as a mechanism for
acquiring PARPi resistance in BRCA2 and p53-null mouse cell-
line33. Therefore, we generated BRCA2 and p53 proﬁcient
PARPi-resistant SUM149 human triple-negative breast cancer
cell lines and investigated PARG protein expression. Our results
detected no observable change in PARG protein expression in
these cells (see Supplementary Fig. 17). However, JA2131-induced
PAR accumulation was comparable to those observed for PC3
cells (Supplementary Fig. 16 and Fig. 5a). These observations
suggest that selective loss of PARG in PARPi resistance may
strictly depend on the underlying genetic context. Indeed, the
general importance of PARG in cancer progression is under-
scored by ﬁnding that catalytically active PARG leads to poor
prognosis and survival, while expression of enzymatically-
defective protein played no part in tumor growth35. This is
consistent with our TCGA database analysis, where most tumors
show higher PARG expression compared to matched, normal
tissues (Fig. 1a) and supports the possible value of a PARGi for
ongoing investigations. Indeed, recently another small molecule
PARGi was shown to delay DNA repair, sensitize cancer cells to
DNA damaging agents, and be effective against PARPi-resistant
tumors57. These data are in concert with the results presented
here, underscoring the potential importance of PARGi cancer
therapeutic.
Overall, our results identify unique targetable structural fea-
tures of PARG that allowed us to identify and optimize a phar-
macologically useful speciﬁc inhibitor. This PARGi is selective,
cell-permeable, prevents PAR removal by PARG, and kills cancer
cells at a level similar to Olaparib. As such, it is expected to
contribute to understanding the roles of PARG and PAR turnover
in multiple aspects of DNA damage responses. PARG is a unique
mammalian protein without paralogs, in contrast to the human
PARP family consisting of 17 related enzymes58. Thus, PARGi
merits testing as potentially producing fewer off-target effects
than PARP inhibitors currently employed as cancer therapeutics.
With these points in mind, we hope that JA2131 will enable many
studies evaluating the potential value of speciﬁcally inhibiting
PARG in various cancer therapeutic strategies.
Methods
Chemicals. All NSC compounds were obtained from the Developmental Ther-
apeutics Program (DTP) repository at NCI/NIH. JA1-5 (JS-2088), JA5-8 (BAS
05169959), and JA5-9 (AO-476/12797006) were purchased from Ryan Scientiﬁc.
JA2-9 (Z57032584), JA5-10 (EN300-63858), and JA5-11 (Z385453050) were pur-
chased from Enamine. JA2-8 (JFD03560SC) was purchased from Maybridge, and
JA5-7 (F3350-0573) was purchased from Life chemicals. All inhibitors were dis-
solved at 40 mM concentrations in DMSO. Hydroxyurea, Nedaplatin, Doxorubicin,
Veliparib, and Olaparib were purchased from SelleckChem. PDD00017273 was
from Tocris.
Protein expression and puriﬁcation. The catalytic domain of rat PARG (residues
385–972) was puriﬁed as described previously18. The human PARG (hPARG)
catalytic domain (residues 389–976) was cloned in pET28a (Novagen) with an N-
terminal His-tag and expressed in E. coli Rosetta cells. hPARG389–976 was puriﬁed
by Ni-NTA (Qiagen) afﬁnity chromatography, loaded onto a heparin column (GE
Healthcare), and then eluted with a salt gradient (0–1M NaCl). hPARG389–976 was
further puriﬁed, using a Superdex 200 size-exclusion chromatography. For the
preparation of PARylated PARP1, the DNA binding domain (DBD; residues
1–374) of human PARP1 and the PARP1C catalytic domain (residues 375–1014)
were puriﬁed as described previously18. For crystallization, human PARG catalytic
domain (residues 448–976) containing the six surface entropy reduction muta-
tions20 was cloned in pET28a vector with an N-terminal His-tag and expressed in
E. coli HMS174 cells expressing GroESL chaperon. The GST-tagged central BRCT
domain of human XRCC1 (BRCT1, residues 294–417; cloned in pGEX-6p1) was
expressed in E. coli Rosetta cells and puriﬁed by glutathione afﬁnity chromato-
graphy. Following cleavage of the GST-tag with PreScission protease (GE
Healthcare), the BRCT1 domain was puriﬁed using a Sephacryl 100 (GE Health-
care) size-exclusion column. For the biotinylation of BRCT1, the BRCT1 domain of
XRCC1 was cloned in pGEX-6p1 with a C-terminal biotin acceptor peptide (BAP)
tag and co-expressed with the BirA biotin ligase (pACYC184-BirA plasmid;
Avidity) in E. coli BL21 (DE3) cells. The biotinylated BRCT1 was puriﬁed using the
same protocol as the GST-BRCT1 protein.
TR-FRET PAR turnover assay. For a high-throughput screening (HTS) of PARG
inhibitors, we developed a high-throughput PARG activity assay using the TR-
FRET system (a manuscript describing the details of this assay will be published
elsewhere). Brieﬂy, the ﬂuorescein molecule (FITC) was enzymatically incorpo-
rated into PARP1 in a reaction containing PARP1C (2 μM), the PARP1 DBD
(2 μM), a 24 mer nicked DNA oligo (2 μM), and a mixture of unlabeled NAD+
(Sigma) and FITC-NAD+ (Trevigen) substrates (total NAD+ concentration of
100 μM). After incubation for 1 h at 37 °C, PARylated PARP1 was desalted using a
PD-10 desalting column (GE healthcare) in a buffer containing 25 mM Tris-HCl
(pH 7.5), 50 mM NaCl, and 0.01% NP-40 and used as the FRET acceptor. The
biotin-tagged BRCT1 domain of XRCC1 (BRCT1, 5 nM) was conjugated with an
equimolar concentration of Tb3+-chelated streptavidin (Life Technologies) in TR-
FRET assay buffer (FRET donor). To monitor dose-response inhibition of PARG
activity (supplementary Table 2), rat PARG385–972 (12.5 nM) was pre-incubated
with compounds for 1 h at room temperature. The reaction was started by the
addition of the FRET pair of FITC-labeled PARP1 (42 nM) and Tb3+-BRCT1
(5 nM). The TR-FRET signal was subsequently monitored for 60 min.
High-throughput screening of PARG inhibitors. Small molecule inhibitors of
PARG were identiﬁed by high-throughput screening (HTS) using the TR-FRET
PAR turnover assay. Compounds (ﬁnal concentration of 6.7 μM) from the NCI
Diversity Set II library (1990 compounds) were pre dispensed into black poly-
styrene 384-well plates (Corning) using a Hummingbird liquid handler (Digilab).
Then, 10 μl of rat PARG385–972 (12.5 nM and 25 nM) were subsequently dispensed
into plates, using a multi-drop combi nL reagent dispenser (Thermo Scientiﬁc) and
incubated with compounds for 1 h at 4 °C. The reaction was initiated by the
addition of 20 μl of the premixed FRET pair of FITC-labeled PARP1 (42 nM) and
Tb3+-BRCT1 (5 nM), and the TR-FRET signal was monitored every 4 min for
40 min (11 data points). Hits were selected by visually comparing the rate of the
TR-FRET signal decrease in each well to that of negative control reactions con-
taining DMSO (Fig. 1b and see Text for details). The HTS was performed at the
High-Throughput Screening Core (HTSC) at Washington University School of
Medicine.
Gel-based PARG activity assay. PARP1C (2 μM) is enzymatically auto-modiﬁed
in a reaction containing the PARP1 DBD (2 μM), a 24 mer nicked DNA oligo
(2 μM), and NAD+ (300 μM) for 1 h at 37 °C, as described previously18. Human
PARG389–976 (1 nM) was pre-incubated with compounds for 1 h at room tem-
perature. The reaction was initiated by the addition of PARylated PARP1 (ﬁnal
concentration of 500 nM) and quenched after 30 min incubation at room tem-
perature by adding SDS-PAGE sample buffer. The gel was visualized by sypro-ruby
staining18 and the retained PARylated PARP1C species were quantiﬁed using
ImageJ59. PARylated PARP1C that migrates slower than unmodiﬁed PARP1C was
quantiﬁed. Control reactions in the absence of PARG (100%) or compound (0%)
were used for normalization of the degree of PARG inhibition by compounds (%
inhibition). The IC50 values were determined by ﬁtting the dose-response data for
each compound to a four-parameter logistic equation using SigmaPlot (Systat
Software Inc.).
To test the speciﬁcity of JA2131, human PARG389–976 (1 nM) was pre-
incubated with JA2131 (5, 10, and 20 μM) in the presence and absence of 0.1%
Triton-X 100 or 0.1 mg/ml BSA for 1 h at room temperature. The reaction was
initiated, quenched, visualized, and quantiﬁed as described above.
Crystallization of human PARG catalytic domain. Crystals of the unliganded
hPARG448–976 were grown by hanging drop vapor diffusion as described pre-
viously20. hPARG448–976 (7.5 mg/ml) was mixed with an equal volume of well
solution, containing 16–24% (w/v) PEG 3350, 0.1 M PCTP (0.04 M sodium pro-
pionate, 0.02 M sodium cacodylate, 0.04M Bis-Tris propane) pH 7.5 and 0.15M
MgCl2 and incubated at 22 °C. To soak inhibitors, crystals were harvested in a
cryoprotectant solution containing 26% PEG 3350, 0.05 M PCTP pH 7.5, 0.1 M
NaCl, 0.15M MgCl2, and 2.5% glycerol. Crystals were soaked with inhibitors at 5
or 10 mM concentrations for 15 h, and then were ﬂash-cooled in liquid nitrogen.
X-ray diffraction data for ﬁve structures were collected in-house at 100 K using a
Rigaku MicroMax007 rotating anode X-ray generator equipped with Xenocs
Mirrors and a MAR image plate, and processed using HKL200060 and
SCALEPACK60,61. All crystals have one hPARG molecule per asymmetric unit and
diffracted to 1.7–2.0 Å resolution. X-ray diffraction data statistics are shown in
Supplementary Table 3 of the online supplementary information. The structures of
hPARG bound to the methylxanthine derivatives were determined by molecular
replacement using Molrep of the CCP4i suite62 with the unliganded hPARG448–976
structure (PDB ID: 4B1G)20 as a search model. The crystallographic models for the
hPARG-inhibitor complexes were constructed using COOT63 and reﬁned using
REFMAC64. Crystallographic data statistics are shown in Supplementary Table 3.
All structural ﬁgures were prepared using PyMOL (www.pymol.org) or Chimera65.
To show reproducibility and conﬁrm the in-house PARG-inhibitor structures,
hPARG crystals were also prepared for synchrotron data collection. hPARG
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crystals were grown as described, soaked with 10 mM JA2131 or JA2120 compound
for 1–2 h, then ﬂash-cooled in liquid nitrogen. X-ray diffraction data were acquired
at Stanford Synchrotron Radiation Lightsource (SSRL) beamline 9-266,67. Data
were processed with XDS to 1.6–1.7 Å66,68, solved by molecular replacement as
described, and reﬁned in Phenix69. Diffraction and crystallographic data statistics
are shown in Supplementary Table 4 of the online supplementary information.
PARG-inhibitor structures determined from synchrotron data were similar in
resolution and conformation to complexes determined from in-house data despite
having a different space group.
Cell culture. PC3, MDA-MB-231 cells were maintained in RPMI 1640, MCF-7 cells
in Eagle’s Minimum Essential Medium (EMEM), MRC-5 cells in Eagle’s Minimum
Essential Medium and Hela and U2OS cells in Dulbecco’s modiﬁed Eagle’s high
glucose medium (DMEM) supplemented with 10% (vol/vol) fetal bovine serum (FBS)
and 1% antibiotic/antimycotic (Lonza) in a humidiﬁed incubator with 10% CO2. All
cell lines were purchased from ATCC and regularly checked for mycoplasma and cell
authentication. SUM 149PT cells were cultured in F-12 Hams (Gibco) supplemented
with 5% fetal bovine serum, insulin, and hydrocortisone. Colony formation assays
were carried out in 6-well plates, 500 cells were used per well and following designated
treatment, and colonies were grown for 2 weeks. Cells were ﬁxed with methanol
(100%), stained with crystal violet and analyzed using a GelCount instrument (Oxford
Optronix Ltd). Crystal Violet C6158 was purchased from Sigma. PARG knockdown
cells were generated by infecting MDA-MB-231 cells with shPARG lentiviral particles
(sc-106355-V, Santa Cruz Biotechnology), which contain a pool of three shRNA
plasmids. After 24 h infection, 3 µg/ml puromycin (Invitrogen) was added and
antibiotic-resistant cells were further expanded and used for experimentation.
Sequence-1; hairpin sequence: GATCCGGAAACGGTACTCTACTAATTCAAGAG
ATTAGTAGAGTACCGTTTCCTTTTT, sense: GGAAACGGUACUCUACUAAtt,
Antisense: UUAGUAGAGUACCGUUUCCtt. Sequence-2; hairpin sequence, GATC
CGAAGGATGCTATTCTGAAATTCAAGAGATTTCAGAATAGCAT-CCTTCTT
TTT, sense: GAAGGAUGCUAUUCUGAAAtt, antisense: UUUCAGAAUAGCAU
CCUUCtt. Sequence-3; hairpin sequence: GATCCGGAAACCGGAGAAACTTAAT
TCAAGAGATTAAGTTTCTCC-GGTTTCCTTTTT, sense: GGAAACCGGAGAAA
CUUAAtt, antisense: UUAAGUUUCUCC-GGUUUCCtt. Control cells were gener-
ated using the same process except that scramble lentiviral particles with scrambled
sequences were used (sc-108080).
Cellular thermal shift assay (CETSA). CETSA was performed as described by
Molina et al.44. Brieﬂy, PC3 cells were treated with 10 μM JA2131 or an equivalent
volume of DMSO for 2 h, washed three times with PBS and extracted for total cell
lysate. Ten percent glycerol was added to the samples before subjecting to heat.
Gradient thermal cycler (C1000 Touch, Bio-Rad) was used to heat samples at 42,
57, 66, 72, 77, and 85 °C for 3 min and chilled on ice for 5 min. Then, samples were
centrifuged at 14,000 rpm for 20 min at 4 °C. Supernatants were carefully removed
and analyzed by western blotting analysis.
Antibodies and western blots. Cells were grown in 6-well plates and 10 cm
dishes, treated with PARGi for 2 h, irradiated and recovered for 1 h before har-
vesting. Cells were irradiated, ranging from 1 to 10 Gy using RAD SOURCE, RS-
2000, Biological System, RadSource.com. Cells were washed with phosphate buffer
and saline (PBS) and lysed with buffer containing 50 mM Hepes, pH 7.5, 1% (vol/
vol) igepal-C630, 1 mg/ml bacitracin, 1 mM EDTA, 10 mM NaF, 1 mM sodium
orthovanadate, 10% (vol/vol) glycerol, 50 mM NaCl, 1 mM PMSF, and Protease
Inhibitor Cocktail Set III (EMD Millipore). The detergent-soluble fraction was used
for western blotting. Cell fractionation was carried out using the Subcellular Pro-
tein Fractionation Kit, (#78840, ThermoFisher) according to the manufacturer’s
instruction. Primary antibodies were purchased from the following sources; Actin,
GAPDH, γH2AX and Histone-H3 was from Cell Signaling Technology. H2AX and
LAMB1 were from Invitrogen/ThermoFisher. PCNA and p53 were from Santa
Cruz Biotechnology. Anti-PAR (10 H) was from EMD Millipore and anti-PARG
was from or Cell Signaling Technology. Anti-PARP1 from Abcam. Secondary
antibodies were conjugated HRP (Cell Signaling) and ECL Clarity was purchased
from Bio-Rad. All primary and secondary antibodies were diluted 1:1000 with 5%
non-fat Blotting Grade Blocking Reagent in 1x TBST, except for anti-PAR 1:500.
Uncropped western data are presented in the Supplementary Fig. 18.
Immuno-staining and imaging. PC3 cells were grown to 75% conﬂuence in 24-
well 25 μm ﬁlm bottom Eppendorf black cell Imaging plates (0030741005), treated
with either DMSO or designated inhibitors for 2 h, irradiated 7 Gy X-ray and
allowed to recover for an hour before ﬁxing with 4% (wt/vol) paraformaldehyde,
pH 8.0. All subsequent steps were performed at pH8.0. Cells were washed 6–7
times with PBS, permeabilized 0.5% Triton X-100 in PBS on ice for 20 min, blocked
overnight with PBS/5% Goat serum/3%BSA/0.5% Triton X-100. Cells were incu-
bated with primary antibody 1:250 dilution in PBS/5%BSA/0.5% Triton X-100
overnight at 4 °C. Following 6× wash with PBS pH 8.0, cells were exposed to
ﬂuorescence-labeled secondary antibody diluted 1:500 in PBS/5%BSA/0.5% Triton
X-100 for 1 h at room temperature. Following 6–7× PBS washes, cells were ﬁxed
again with 4% PFA at room temperature for 20 min. After a further 6× PBS washes
cells were imaged in PBS buffer using ImageXpress high-content imager (Mole-
cular Devices Inc). Statistical analysis was performed with MetaXpress Software.
Sulforhodamine B (SRB) cytotoxicity assay. Cells were plated in 96-well plates,
treated as designated in reduced 5% FBS and ﬁxed with trichloroacetic acid after
72 h, as previously described by43. PARG inhibitor JA2131 was titrated typically
from 300 to 0.15 μM. Colorimetric or ﬂuorescence analysis was performed in a
FlexStation 3, using SoftMax Pro 7.0, Molecular Devices. Normalized graphs were
generated with Prism 8 software, non-linear 4-parameter data ﬁtting was per-
formed for IC50 calculation.
DNA ﬁber assay. DNA ﬁber assay was conducted as described previously (Castillo
et al. 2014). Brieﬂy, cells pretreated with JA2131 (10 µM) or DMSO for 2 h were
labeled with 100 µM CldU for 30 min and exposed to 250 µM IdU (with or without
0.4 mM hydroxyurea treatment) for another 30 min or 3 h. After labeling and
treatment, cells were lysed and DNA ﬁbers stretched onto glass slides. Immuno-
ﬂuorescence was carried out using α-IdU/α-BrdU (BD Biosciences) and α-CldU/α-
BrdU (Abcam) and secondary antibodies, including Alexa Fluor 488 (green) and
Alexa Fluor 555 (Invitrogen). Images were taken using a Nikon 80 microscope and
analyzed using ImageJ software. Statistics were calculated using Prism software. 5-
Chloro-2’-deoxyuridine (CIdU) and 5-Iodo-2’-deoxyuridine (IdU) were
from Sigma.
TCGA analysis. We used the TCGA-Assembler suite70 with the Assay Platform
option set to gene to obtain the normalized Rsem RNA-seq gene expression data
from TCGA (https://cancergenome.nih.gov) project. Data were processed with
in-house scripts (C++ and Bash) and plotted with the R package “ggpllot2” and
“ggpubr”.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data supporting the ﬁndings of this manuscript are available from the corresponding
author upon reasonable request. Coordinates and structure-factor ﬁles for human PARG
complexed with JA2-4, JA2-8, JA2-9, JA2120, and JA2131 have been deposited in the
Protein Data Bank, with accession codes; 6O9X, 6O9Y, 6OA0, 6OA1, and 6OA3.
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